Clinical Trial Update: Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 study of irinotecan liposome injection (ONIVYDE) in small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: Ipsen | Conditions: Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-10-17